- Experience. Mayo Clinic hematologists diagnose and care for hundreds of patients with monoclonal gammopathy of undetermined significance (MGUS) each year. Experienced pathologists are skilled in the testing and identification of the M protein and determining its potential risk of progression to cancer.
- Research Advances. Numerous Mayo Clinic researchers are studying MGUS to better understand it and to improve treatment options. Mayo Clinic researchers developed a risk-assessment model that can predict risk of progression of monoclonal gammopathy of undetermined significance to multiple myeloma.
- Coordinated care. A specialist in blood diseases (hematologist) will oversee your care and bring in other specialists as needed, including neurologists if nerve damage is suspected, nephrologists to prevent kidney failure and dermatologists if skin lesions occur. Access to specialists, testing and treatment is available in one convenient location and can be accomplished in a few days.
Mayo Clinic: Answers you can trust
At Mayo Clinic, we assemble a team of specialists who take the time to listen and thoroughly understand your health issues and concerns. We tailor the care you receive to your personal health care needs. You can trust our specialists to collaborate and offer you the best possible outcomes, safety and service.
Mayo Clinic is a not-for-profit medical institution that reinvests all earnings into improving medical practice, research and education. We're constantly involved in innovation and medical research, finding solutions to improve your care and quality of life. Your doctor or someone on your medical team is likely involved in research related to your condition.
Our patients tell us that the quality of their interactions, our attention to detail and the efficiency of their visits mean health care — and trusted answers — like they've never experienced.
Why Choose Mayo Clinic
What Sets Mayo Clinic Apart
May. 17, 2013
- Rajkumar SV. Diagnosis of monoclonal gammopathy of undetermined significance. http://www.uptodate.com/home. Accessed April 3, 2013.
- Rajkumar SV. Clinical course and management of monoclonal gammopathy of undetermined significance. http://www.uptodate.com/home. Accessed April 3, 2013.
- Blade J. Monoclonal gammopathies of undetermined significance. New England Journal of Medicine. 2006;355:2765.
- Rajkumar SV, et al. Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: Implications for recategorizing disease entities in the presence of evolving scientific evidence. Mayo Clinic Proceedings. 2010;85:945.
- Therneau TM. Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition. Mayo Clinic Proceedings. 2012;87:1071.